“COST-EFFECTIVENESS ANALYSIS OF ADJUVANT OSIMERTINIB IN RESECTED EGFR-MUTATED EARLY-STAGE NON-SMALL CELL LUNG CANCER IN THAILAND”. 2025. Proceedings of the International Conference on Public Health 9 (1): 45-67. https://doi.org/10.17501/24246735.2024.9105.